A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma

Br J Haematol. 2013 Mar;160(5):714-7. doi: 10.1111/bjh.12154. Epub 2012 Dec 4.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter

MeSH terms

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Boronic Acids / administration & dosage
  • Boronic Acids / adverse effects
  • Bortezomib
  • Creatinine / blood
  • Dehydration / etiology
  • Drug Resistance, Neoplasm
  • Female
  • Humans
  • Kidney Failure, Chronic / blood
  • Kidney Failure, Chronic / etiology
  • Male
  • Middle Aged
  • Multiple Myeloma / blood
  • Multiple Myeloma / complications
  • Multiple Myeloma / drug therapy*
  • Pyrazines / administration & dosage
  • Pyrazines / adverse effects
  • Recurrence
  • Remission Induction
  • Resveratrol
  • Salvage Therapy*
  • Stilbenes / administration & dosage
  • Stilbenes / adverse effects
  • Treatment Failure
  • Vomiting / chemically induced
  • Vomiting / complications

Substances

  • Boronic Acids
  • Pyrazines
  • Stilbenes
  • Bortezomib
  • Creatinine
  • Resveratrol

Associated data

  • ClinicalTrials.gov/NCT00920556